APREA THERAPEUTICS, INC.

(APRE)
  Rapport
Temps Différé Nasdaq  -  27/05 22:00:00
0.8200 USD   +1.86%
25/05APREA THERAPEUTICS, INC. : Berenberg Bank conserve son opinion neutre
ZM
16/05Aprea Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
CI
16/05ATRIN PHARMACEUTICALS LLC A ACQUIS APREA THERAPEUTICS, INC. (NASDAQGS : APRE) dans le cadre d'une opération de fusion inversée.
CI
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur APREA THERAPEUTICS, INC.
17/05APREA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acqui..
17/05APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to NASDAQ Composite Index
16/05APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
16/05TRANSCRIPT : Aprea Therapeutics, Inc. - Special Call
16/05APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
16/05Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports Firs..
16/05Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
16/05APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from NASDAQ Composite Index
16/05ATRIN PHARMACEUTICALS LLC ACQUIRED A : APRE) in a reverse merger transaction.
15/03APREA THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results and Provi..
15/03APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
15/03Aprea Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, ..
15/03Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Prov..
15/03Aprea Therapeutics, Inc. Provides Update on Business Operations
15/03Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December..
13/01TRANSCRIPT : Aprea Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conferen..
13/01APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
06/01Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on T..
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from NASDAQ Biotechnology Index
2021Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant..
2021Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azaci..
2021Aprea Therapeutics, Inc. Announces Updated Results from Its Phase 2 Trial Evaluating Ep..
2021APREA THERAPEUTICS : Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Ma..
2021APREA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
2021Aprea Therapeutics Says FDA Has Removed Its Clinical Hold on Study of Eprenetapopt for ..
2021APREA THERAPEUTICS : FDA Lifts Hold on Eprenetapopt Study in Lymphoid Malignancies
2021Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid M..
2021Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid M..
2021Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on ..
2021APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
2021Aprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
2021Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on ..
2021Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd..
2021Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd..
2021Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd..
2021INSIDER SELL : Aprea Therapeutics
2021APREA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
2021Aprea Therapeutics, Inc. Announces Resignation of Johan Christenson from the Board of D..
2021INSIDER SELL : Aprea Therapeutics
2021INSIDER SELL : Aprea Therapeutics
2021INSIDER SELL : Aprea Therapeutics
2021INSIDER SELL : Aprea Therapeutics
2021APREA THERAPEUTICS : Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advan..
2021Aprea Therapeutics, Inc. Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) i..
2021Top Premarket Gainers
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from S&P Global BMI Index
2021APREA THERAPEUTICS : to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Soli..
2021Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Sol..
2021NORTH AMERICAN MORNING BRIEFING : Stock Furures -3-
2021NORTH AMERICAN MORNING BRIEFING : Weak Chinese -4-
2021APREA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
2021APREA THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides Update on ..
2021APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other Events, Fi..
2021Aprea Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second..
2021Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on..
2021APREA THERAPEUTICS : Says FDA Places Clinical Hold on Lymphoid Malignancy Program
2021Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
2021Aprea Therapeutics, Inc. Announces Clinical Hold on Lymphoid Malignancy Program
2021APREA THERAPEUTICS : FDA Puts Clinical Hold on Lymphoid Malignancy Program
2021SECTOR UPDATE : Health Care Pulls Back Ahead of Friday Opener
2021TRANSCRIPT : Aprea Therapeutics, Inc. - Special Call
2021Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs
2021APREA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
2021APREA THERAPEUTICS : Announces a Partial Clinical Hold on Myeloid Malignancy Programs
2021APREA THERAPEUTICS : Phase 2 Trial of Eprenetapopt With Azacitidine Yields Positive Result..
2021APREA THERAPEUTICS : Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azaci..
2021Aprea Therapeutics, Inc. Announces Positive Results from Phase 2 Trial of Eprenetapopt ..
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2500 Index
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2000 Growth Index
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 3000 Growth Index
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2500 Growth Index
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 3000E Index
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to Russell 3000E Value Index
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to Russell Microcap Value Index
2021APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2000 Dynamic Index
1  2  3Suiv.